Multiple myeloma is most commonly diagnosed in individuals of age 65 to 70 years. However, recent statistics show increasing incidence and earlier age of onset, with about 10 to 15 percent of patients under 45 years of age. Approximately 50,000 Americans are diagnosed as suffering from multiple myeloma. In the U.S. this year alone, more than 14,000 individuals will be diagnosed with multiple myeloma and more than 11,000 lives will be lost to this disease.
Bone metastases are one of the most common causes of morbidity in cancer patients.
There are 250,000 to 300,000 new cases of bone metastases diagnosed every year. Presently, there is no known cure for multiple myeloma. However, for active myeloma, various treatment options are available, and most are aimed at stabilizing the disease and increasing survival rates and duration with improved quality of life. The Program offers a comprehensive array of full-scope services and individualized treatment options based on the specific challenges of a patient's disease charatacteristics and stage. Through its clinical trials, the Program makes cutting-edge, novel therapeutics accessible to patients with multiple myeloma.